Free PLX5622 crystal form and preparation method thereof
Patent Information
- Application Number
- CN202380033332.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-15
- Filing Date
- 2023-04-14
- Publication Date
- 2024-11-15
AI Technical Summary
No crystal form has been found for the existing PLX5622 compound, making it difficult to quickly and safely reduce microglia, and its efficacy has not been fully exerted.
Discovered and prepared multiple crystal forms of the PLX5622 compound, including crystal forms A, B, C, D, E and F, and provided methods for preparing these crystal forms, and confirmed their structures through X-ray powder diffraction patterns and other analytical means and stability, preferred preparation methods include spray drying and crystallization.
The prepared new crystal form has good stability and high purity. In particular, crystal form B is significantly better than crystal form A in clearing microglia and is suitable for industrial production, providing a new direction for pharmaceutical development.
Smart Images

Figure CN118974047A_ABST
Abstract
Description
A free PLX5622 crystal form and preparation method thereof
[0001] This application claims priority to Chinese patent application No. 202210400114.X, filed April 15, 2022. This application incorporates the entire text of the aforementioned Chinese patent application. Technical Field
[0002] The present invention relates to a new crystal form of free PLX5622 and a preparation method thereof, belonging to the technical field of medicine and chemistry. Background Art
[0003] PLX5622 is a CSF1R colony stimulating factor-1 receptor inhibitor, and its chemical structure is shown in Formula I:
[0004] PLX5622 is a highly selective, blood-brain barrier-penetrating, orally available CSF1R inhibitor (IC 50 =0.016μM; K i =5.9nM), PLX5622 can deplete microglia and reduce the number of perivascular macrophages and circulating immune cells. The study found that depleting microglia with the CSF1R inhibitor PLX5622 partially prevented the short-term memory impairment caused by prolonged Ang II infusion, and the cognitive improvements achieved with PLX5622 were independent of changes in blood-brain barrier permeability. This is an important step forward in the development of CSF1R therapeutics, but further research is needed to develop a treatment regimen that can rapidly and safely reduce microglia in patients within a short period of time.
[0005] CN102695417A (WO2011057022A1) was prepared by reference to Scheme 25. The PLX5622 compound obtained by reaction treatment and concentration was purified by silica gel column (elution with 20-100% ethyl acetate in hexane solution) and concentrated to obtain an amorphous white solid; Nature communications, 2019, 10(1): 3758. The literature discloses that the PLX5622 free base has an mp of 189°C.
[0006] However, to date, no crystalline form of PLX5622 has been discovered. During in-depth pharmaceutical research on PLX5622, the present inventors unexpectedly discovered multiple different crystalline forms. None of the specific crystalline forms A to F described herein are known for the compound of Formula I. Furthermore, the crystalline form of Compound I provided by the present invention exhibits outstanding efficacy in clearing microglia.
[0007] Summary of the Invention
[0008] Against the background of the above technology, the present invention satisfies these needs by providing a solid form of a compound of formula I. The present invention provides a crystalline form of a compound of formula I.
[0009] The present invention also provides pharmaceutical compositions comprising solid forms of the compound of formula I. The present disclosure also provides methods for preparing solid forms and their use in preparing medicaments for treating CSF1R-mediated diseases.
[0010] The present invention provides polycrystalline forms of compound I, and a preferred technical solution is provided. The present invention provides PLX5622 (compound formula I) in free form with good stability, crystal forms A, B, C, D, E and F of compound formula I, and a preparation method thereof.
[0011] The free form of PLX5622 (compound of Formula I) described in the present invention has a chemical name: 6-fluoro-N-((5-fluoro-2-methoxypyridin-3-yl)methyl)-5-((5-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)pyridin-2-amine, and a structural formula as shown in Formula I:
[0012] The present invention provides a crystalline form A of a compound of formula I. One embodiment relates to a crystalline form A of a free form of PLX5622 (a compound of formula I). The crystalline form A of the compound of formula I has characteristic peaks at diffraction angles 2θ of 8.60±0.2°, 10.50±0.2°, and 13.80±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source.
[0013] Another object of the present invention is to provide a crystalline form A of the compound of formula I, wherein the crystalline form A of the compound of formula I is an anhydrous crystalline form.
[0014] In some embodiments, the crystalline form A of the compound of Formula I is free of solvent, and the solvent comprises water.
[0015] The present invention provides a crystalline form A of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.60±0.2°, 13.80±0.2°, 18.38±0.2°, and 20.90±0.2°.
[0016] The present invention provides a crystalline form A of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.60±0.2°, 10.50±0.2°, 13.80±0.2°, 14.66±0.2°, 17.18±0.2°, 18.38±0.2°, 20.90±0.2° and 25.98±0.2°.
[0017] The present invention provides a crystalline form A of a compound of formula I, wherein the X-ray powder diffraction pattern thereof has 2θ values of 8.60±0.2°, 9.18±0.2°, 10.50±0.2°, 12.94±0.2°, 13.80±0.2°, 14.66±0.2°, 16.67±0.2°, 17.18±0.2°, 17.70±0.2°, 18.38±0.2°, 18.90±0.2°, 19.46±0.2°, 20.0 There are characteristic peaks at 8±0.2°, 20.90±0.2°, 22.02±0.2°, 23.86±0.2°, 24.74±0.2°, 25.62±0.2°, 25.98±0.2°, 26.70±0.2°, 27.40±0.2°, 27.70±0.2°, 28.48±0.2°, 29.44±0.2°, 29.76±0.2°, 30.86±0.2° and 31.88±0.2°.
[0018] In one embodiment of the present invention, the present invention provides a method for preparing Form A of the compound of Formula I, which comprises recrystallizing Form A of the compound of Formula I from a mixture of an alcohol solvent such as methanol, ethanol, isopropanol, and / or water.
[0019] Further preferably, the crystalline form A of the compound of formula I of the present invention has an XRPD pattern consistent with Figure 1.
[0020] Another embodiment relates to crystalline PLX5622 (compound of formula I) in free form, form B of the compound of formula I. Form B of the compound of formula I has characteristic peaks at diffraction angles 2θ of 5.90±0.2°, 15.6±0.2°, and 17.2±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source.
[0021] Another embodiment relates to crystalline PLX5622 (compound of Formula I) in free form, Form B of the compound of Formula I. Form B of the compound of Formula I has characteristic peaks at diffraction angles 2θ of 5.90±0.2°, 15.65±0.2°, and 17.20±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source.
[0022] In some embodiments, the crystalline form B of the compound of Formula I is free of solvent, and the solvent comprises water.
[0023] Another object of the present invention is to provide a crystalline form B of the compound of formula I, wherein the crystalline form B of the compound of formula I is an anhydrous crystalline form.
[0024] Preferably, the crystalline form B of the compound of formula I according to the present invention has an X-ray powder diffraction pattern further having characteristic peaks at one or more of the following 2θ values: 9.18±0.2°, 17.84±0.2°, 21.64±0.2°, 22.50±0.2° and 27.64±0.2°; more preferably, its X-ray powder diffraction pattern further has characteristic peaks at one or more of the following 2θ values: 11.70±0.2°, 14.16±0.2°, 19.86±0.2°, 21.99±0.2°, 23.88±0.2°, 24.28±0.2°, 24.52±0.2°, 28.10±0.2° and 28.40±0.2°.
[0025] The present invention provides a crystalline form B of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 5.90±0.2°, 15.65±0.2°, 17.20±0.2° and 22.50±0.2°.
[0026] The present invention provides a crystalline form B of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 5.90±0.2°, 9.18±0.2°, 15.65±0.2°, 17.20±0.2°, 17.84±0.2°, 21.64±0.2°, 22.50±0.2° and 27.64±0.2°.
[0027] Preferably, the crystalline form B of the compound of formula I according to the present invention has an X-ray powder diffraction pattern having characteristic peaks at 2θ values of 5.90±0.2°, 9.18±0.2°, 11.70±0.2°, 14.16±0.2°, 15.65±0.2°, 17.20±0.2°, 17.84±0.2°, 19.86±0.2°, 21.64±0.2°, 21.99±0.2°, 22.50±0.2°, 23.88±0.2°, 24.28±0.2°, 24.52±0.2°, 27.64±0.2°, 28.10±0.2° and 28.40±0.2°.
[0028] Further preferably, the Form B of the compound of Formula I of the present invention has an XRPD pattern consistent with Figure 2.
[0029] Further preferably, the differential scanning calorimetry (DSC) spectrum of the crystalline form B of the compound of formula I of the present invention has two endothermic peaks at 181°C±4°C and 188°C±4°C.
[0030] Further preferably, the DSC spectrum of Form B of the compound of Formula I of the present invention is substantially as shown in FIG3 .
[0031] Further preferably, the differential scanning calorimetry (TGA) spectrum of Form B of the compound of Formula I of the present invention is substantially as shown in FIG17 .
[0032] Further preferably, the differential scanning calorimetry (DSC) spectrum of Form B of the compound of Formula I of the present invention is shown in Figure 3, wherein the Form B has endothermic peaks at least near 181°C±4°C and 188°C±4°C.
[0033] Further preferably, the DSC analysis method of Form B of the compound of Formula I of the present invention is as follows: the scanning rate is 10°C / min.
[0034] The present invention also provides a preparation method for obtaining the crystalline form B of the compound of formula I by rapidly removing the solvent.
[0035] The method for preparing Form B of the compound of Formula I described herein comprises dissolving the compound of Formula I in a solvent selected from the group consisting of ethers, alkanes, alcohols, esters, or any combination thereof, and then removing the solvent to obtain the compound of Formula I. The method for preparing Form B of the compound of Formula I described herein comprises obtaining the compound by rapidly removing the solvent, such as by distillation or spray drying.
[0036] The method for preparing Form B of the compound of Formula I described herein comprises obtaining the compound by rapid solvent removal, such as dissolution in an ethereal solvent followed by spray drying. The volume-to-mass ratio of the ethereal solvent to the compound of Formula I can be 15-100 mL / g, for example, 30 mL / g. The ethereal solvent can be tetrahydrofuran.
[0037] The preferred technical solution of the present invention provides a method for preparing Form B of the compound of Formula I, comprising the following steps:
[0038] (1) dissolving the compound of formula I in tetrahydrofuran solution;
[0039] (2) Spray drying quickly removes solvent;
[0040] (3) obtaining Form B of the compound of Formula I;
[0041] (4) The crystalline form B of the compound of formula I obtained in (3) can be further dried.
[0042] The present invention also provides a method for preparing Form B of the compound of Formula I by crystallization.
[0043] The method for preparing Form B of the compound of Formula I described herein comprises dissolving the compound of Formula I in a solvent such as an amide (N,N-dimethylformamide), an alcohol, an ester, or any combination thereof, and then adding an antisolvent to crystallize the compound of Formula I. The antisolvent referred to herein refers to a solvent in which the compound of Formula I has a low solubility, and can be selected from alkanes or water. Furthermore, the introduction of the antisolvent can reduce the solubility of the compound of Formula I in a solution other than the solvent, thereby precipitating Form B of the compound of Formula I as a solid.
[0044] Further preferably, when Form B of the compound of Formula I is prepared by crystallization, the method comprises the following steps: mixing water and a mixture X to obtain a mixed solution A, and crystallizing; the mixture X comprises the compound of Formula I and N,N-dimethylacetamide; the volume mass ratio of N,N-dimethylacetamide to the compound of Formula I is 8 mL / g, and the volume mass ratio of water to the compound of Formula I is 3 mL / g. The crystallization time can be 0.1-80 hours, for example, 1 hour. The crystallization temperature can be -15-60°C, for example, 5°C.
[0045] Further preferably, when crystallization is used to prepare Form B of the compound of Formula I, the method further comprises the following steps: mixing the mixed solution A with water, wherein the volume mass ratio of the water to the compound of Formula I is 5 mL / g, and continuing crystallization. The crystallization time can be 0.5-72 hours, for example, 0.5 hours. The crystallization temperature can be 0-25°C, for example, 5°C.
[0046] More preferably, when the crystal form B of the compound of formula I is prepared by crystallization, the method further includes the following post-treatments: filtration and vacuum drying. The vacuum drying temperature can be 10-80°C, for example 60°C.
[0047] The method for preparing a single crystalline Form B of PLX5622 with good stability in the free state described in the present invention is intended to be suitable for industrial production. The crystalline Form B prepared by this method has significantly better pharmaceutical effects than the crystalline Form A. Compared with the crystalline Form A of the compound of Formula I, the crystalline Form B has an outstanding effect in clearing microglia, and the 7-day or 14-day clearance rate of microglia is better than that of the crystalline Form A.
[0048] Another embodiment relates to crystalline PLX5622 (compound of Formula I) in free form, Form C of the compound of Formula I. Form C of the compound of Formula I has characteristic peaks at diffraction angles 2θ of 8.24±0.2°, 13.16±0.2°, and 16.40±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source.
[0049] Another object of the present invention is to provide a crystalline form C of the compound of formula I, which is a hydrate crystalline form.
[0050] The present invention provides a crystalline form C of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.24±0.2°, 13.16±0.2°, 16.40±0.2°, 18.38±0.2° and 27.66±0.2°.
[0051] The present invention provides a crystalline form C of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.24±0.2°, 13.16±0.2°, 13.74±0.2°, 16.40±0.2°, 17.72±0.2°, 18.38±0.2°, 20.42±0.2° and 27.66±0.2°.
[0052] Preferably, the crystalline form C of the compound of formula I according to the present invention has an X-ray powder diffraction pattern having characteristic peaks at 2θ values of 8.24±0.2°, 9.26±0.2°, 13.16±0.2°, 13.74±0.2°, 16.40±0.2°, 17.72±0.2°, 18.38±0.2°, 20.42±0.2°, 24.72±0.2°, 27.24±0.2° and 27.66±0.2°.
[0053] Further preferably, the Form C of the compound of Formula I of the present invention has an XRPD pattern consistent with Figure 6.
[0054] An embodiment of the present invention also provides a method for preparing Form C.
[0055] The present invention also provides a method for preparing Form C of the compound of Formula I, wherein the compound of Formula I is crystallized using a mixed solvent of N,N-dimethylacetamide DMAC and water; preferably, a mixed solvent of 14 times the mass (g) of the compound of Formula I by volume (mL) of N,N-dimethylacetamide DMAC and 7.5 times the volume (mL) of water is used.
[0056] Another embodiment relates to crystalline PLX5622 (compound of formula I) in free form, form D of the compound of formula I. Form D of the compound of formula I has characteristic peaks at diffraction angles 2θ of 11.70±0.2°, 17.76±0.2°, and 15.92±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source.
[0057] Another object of the present invention is to provide a crystalline form D of the compound of formula I, wherein the crystalline form is a one-molecule N,N-dimethylacetamide DMAC solvent compound.
[0058] The present invention provides a crystalline form D of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 11.70±0.2°, 17.76±0.2°, 15.92±0.2°, 20.46±0.2° and 29.08±0.2°.
[0059] The present invention provides a crystalline form D of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.00±0.2°, 10.26±0.2°, 11.70±0.2°, 12.50±0.2°, 15.92±0.2°, 17.76±0.2°, 20.46±0.2° and 29.08±0.2°.
[0060] Preferably, the crystalline form D of the compound of formula I according to the present invention has an X-ray powder diffraction pattern having characteristic peaks at 2θ values of 8.00±0.2°, 10.26±0.2°, 11.70±0.2°, 12.50±0.2°, 15.92±0.2°, 17.76±0.2°, 20.46±0.2°, 26.88±0.2°, 27.08±0.2°, 27.34±0.2°, 29.08±0.2° and 29.36±0.2°.
[0061] Further preferably, the crystalline form D of the compound of formula I of the present invention has an XRPD pattern consistent with Figure 7.
[0062] Further preferably, the DSC spectrum of the crystalline form D of the compound of formula I of the present invention has two absorption peaks at 50°C-100°C and 189°C±3°C.
[0063] Further preferably, the DSC spectrum of Form D of the compound of Formula I of the present invention is substantially as shown in FIG8 .
[0064] Further preferably, the differential scanning calorimetry (DSC) spectrum of Form D of the compound of Formula I of the present invention is shown in Figure 8, wherein the Form D has two relatively obvious sharp endothermic peaks in the range of 20°C-250°C, one of which is around 50°C-100°C, and the other is in the range of 189°C±3°C.
[0065] Further preferably, the DSC analysis method of the crystalline form D of the compound of formula I of the present invention is as follows: the scanning rate is 10°C / min.
[0066] Further preferably, the differential scanning calorimetry (TGA) spectrum of the crystalline form D of the compound of formula I of the present invention shows a weight loss of 18% at 50-100°C.
[0067] Further preferably, the TGA spectrum of Form D of the compound of Formula I of the present invention is substantially as shown in FIG9 .
[0068] Further preferably, the differential scanning calorimetry (TGA) spectrum of Form D of the compound of Formula I of the present invention is shown in Figure 9, wherein the Form D has an obvious weight loss at 50-100 ° C, and the weight loss mass percentage is about 18%, corresponding to one molecule of N, N-dimethylacetamide DMAc. Combined with nuclear magnetic resonance, Form D is determined to be a molecule of N, N-dimethylacetamide DMAC solvent compound.
[0069] Further preferably, the TGA analysis method of the crystalline form D of the compound of formula I of the present invention is as follows: the scanning rate is 10° C. / min.
[0070] The present invention also provides a method for preparing Form D of the compound of Formula I, wherein Form D of the compound of Formula I is obtained by crystallization using a mixed solvent of N,N-dimethylacetamide DMAC and water; preferably, a mixed solvent of 4-7 times the mass (g) of the compound of Formula I by volume (mL) of N,N-dimethylacetamide DMAC and 1-2.5 times the volume (mL) of water is used.
[0071] Another embodiment relates to crystalline PLX5622 (compound of formula I) in free form, form E of the compound of formula I. Form E of the compound of formula I has characteristic peaks at diffraction angles 2θ of 15.40±0.2°, 18.02±0.2°, and 19.68±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source.
[0072] Another object of the present invention is to provide a crystalline form E of the compound of formula I, wherein the crystalline form is a one-molecule N,N-dimethylacetamide DMAC solvent compound.
[0073] The present invention provides a crystalline form E of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 15.40±0.2°, 18.02±0.2°, 19.68±0.2°, 21.72±0.2° and 26.20±0.2°.
[0074] The present invention provides a crystalline form E of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 10.24±0.2°, 13.44±0.2°, 15.40±0.2°, 17.16±0.2°, 18.02±0.2°, 19.68±0.2°, 20.82±0.2°, 21.72±0.2° and 26.20±0.2°.
[0075] Preferably, the crystalline form E of the compound of formula I of the present invention has an X-ray powder diffraction pattern at 2θ values of 8.98±0.2°, 9.86±0.2°, 10.24±0.2°, 13.44±0.2°, 15.40±0.2°, 16.14±0.2°, 17.16±0.2°, 18.02±0.2°, 19.68±0.2°, 20.24±0.2°. , 20.82±0.2°, 21.72±0.2°, 22.82±0.2°, 24.36±0.2°, 25.54±0.2°, 26.20±0.2°, 27.32±0.2°, 28.10±0.2°, 30.62±0.2°, 31.38±0.2°, 32.14±0.2° and 38.06±0.2°.
[0076] Further preferably, the crystalline form E of the compound of formula I of the present invention has an XRPD pattern consistent with Figure 10.
[0077] Further preferably, the DSC spectrum of the crystalline form E of the compound of formula I of the present invention has two absorption peaks at 107±3°C and 177±3°C, and one exothermic peak at 111±3°C.
[0078] Further preferably, the DSC spectrum of Form E of the compound of Formula I of the present invention is substantially as shown in Figure 11.
[0079] Further preferably, the differential scanning calorimetry (DSC) spectrum of Form E of the compound of Formula I according to the present invention is shown in Figure 11, wherein Form E has multiple endothermic and exothermic peaks in the range of 20°C-250°C. One relatively obvious endothermic peak is around 90°C-120°C, and another is in the range of 150°C-200°C.
[0080] Further preferably, the DSC analysis method of the crystalline form E of the compound of formula I of the present invention is as follows: the scanning rate is 10°C / min.
[0081] Further preferably, the TGA spectrum of the crystalline form E of the compound of formula I of the present invention shows a weight loss of 16% at 50-110°C.
[0082] Further preferably, the TGA spectrum of Form E of the compound of Formula I of the present invention is substantially as shown in Figure 12.
[0083] Further preferably, the differential scanning calorimetry (TGA) spectrum of Form E of the compound of Formula I according to the present invention is shown in Figure 12, wherein within the scanning temperature range of 20-300°C, the Form E exhibits an obvious weight loss, with a weight loss mass percentage of approximately 17%, which indicates that it is a molecule of N,N-dimethylacetamide DMAC solvent compound.
[0084] Further preferably, the TGA analysis method of the crystalline form E of the compound of formula I of the present invention is as follows: the scanning rate is 10° C. / min.
[0085] The embodiment of the present invention also provides a method for preparing the crystalline form E of the compound of formula I, using a mixed solvent of DMAC and water to crystallize the compound of formula I, preferably at 25 ° C., using 8 times the volume (mL) of N, N-dimethylacetamide DMAC and 5 times the volume (mL) of water as the mass number (g) of the compound of formula I, and then cooling to 5 ° C., keeping the crystal for 1-2h, and then adding 7 times the volume (mL) of water as the mass number g of the compound of formula I, keeping the crystal for 0.5h, and filtering to obtain.
[0086] Another embodiment relates to crystalline PLX5622 (compound of formula I) in free form, Form F of the compound of formula I. Form F of the compound of formula I has characteristic peaks at diffraction angles 2θ of 8.98±0.2°, 9.82±0.2°, and 17.08±0.2°2θ in an X-ray powder diffraction pattern using a Cu-Kα radiation source.
[0087] Another object of the present invention is to provide a crystalline form F of the compound of formula I, wherein the crystalline form is a THF solvent compound.
[0088] The present invention provides a crystalline form F of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.98±0.2°, 9.82±0.2°, 17.08±0.2° and 19.72±0.2°.
[0089] The present invention provides a crystalline form F of a compound of formula I, whose X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.98±0.2°, 9.82±0.2°, 17.08±0.2°, 18.00±0.2°, 19.72±0.2°, 20.96±0.2°, 22.14±0.2° and 25.00±0.2°.
[0090] Preferably, the crystalline form F of the compound of formula I according to the present invention has an X-ray powder diffraction pattern having characteristic peaks at 2θ values of 8.03±0.2°, 8.98±0.2°, 9.92±0.2°, 16.10±0.2°, 17.08±0.2°, 18.00±0.2°, 19.72±0.2°, 20.96±0.2°, 22.14±0.2°, 24.26±0.2°, 25.00±0.2°, 27.18±0.2°, 28.60±0.2°, 29.75±0.2°, 34.54±0.2° and 36.50±0.2°.
[0091] Further preferably, the Form F of the compound of Formula I of the present invention has an XRPD pattern consistent with Figure 13.
[0092] Further preferably, the DSC spectrum of the crystalline form F of the compound of formula I of the present invention has two absorption peaks at 79±3°C and 190±3°C, and one exothermic peak at 182±3°C.
[0093] Further preferably, the DSC spectrum of Form F of the compound of Formula I of the present invention is substantially as shown in Figure 14.
[0094] Further preferably, the differential scanning calorimetry (DSC) spectrum of Form F of the compound of Formula I according to the present invention is shown in Figure 14, wherein Form F has multiple endothermic and exothermic events in the range of 20°C-250°C. Among them, there are three relatively obvious and sharp endothermic peaks, one of which is around 78°C, one is in the range of 182±3°C, and another is in the range of 190°C±3°C.
[0095] Further preferably, the DSC analysis method of the crystalline form F of the compound of formula I of the present invention is as follows: the scanning rate is 10°C / min.
[0096] Further preferably, the TGA spectrum of the crystalline form F of the compound of formula I of the present invention shows a weight loss of 15% at 50-100°C.
[0097] Further preferably, the TGA spectrum of Form F of the compound of Formula I of the present invention is substantially as shown in Figure 15.
[0098] Further preferably, the differential scanning calorimetry (TGA) spectrum of Form F of the compound of Formula I according to the present invention is shown in Figure 15, wherein within the scanning temperature range of 20-300°C, the Form F has an obvious weight loss of about 15%, which is identified as a THF solvent compound.
[0099] The present invention also provides a method for preparing Form F of the compound of Formula I, preferably by crystallization in tetrahydrofuran solution to obtain the compound of Formula I. The volume-to-mass ratio of the tetrahydrofuran solvent to the compound of Formula I can be 6-100 mL / g, for example 7 mL / g.
[0100] One embodiment of the present invention is a pharmaceutical composition comprising a compound selected from the group consisting of Form A of the compound of Formula I, Form B of the compound of Formula I, Form C of the compound of Formula I, Form D of the compound of Formula I, Form E of the compound of Formula I, or Form F of the compound of Formula I, and a pharmaceutically acceptable excipient.
[0101] Another embodiment relates to a method for treating a subject having or at risk of glioblastoma, or another embodiment relates to a method for treating a subject with Alzheimer's disease (AD), or another embodiment relates to a method for restoring the performance of microglia to improve rare and common neurodegenerative diseases. The method comprises administering to the subject a therapeutically effective amount of a compound of Formula I, Form A, Form B, Form C, Form D, Form E, Form F, or a combination thereof.
[0102] In some embodiments, one or more solid, crystalline or polymorphic forms of a compound of Formula I as described herein, or a composition thereof as described herein, can be used to prepare a medicament for treating a disease or condition selected from the group consisting of: for example, amnesia, Alzheimer's disease, cognitive impairment, motor and sensory dysfunction, improving cognitive impairment after TBI, subcortical arteriosclerotic leukoencephalopathy type dementia, dementia with Lewy bodies, holoprosencephaly, microcephaly, cerebral palsy, addiction, dependence, tremor, Wilson's disease , vascular dementia, multi-infarct dementia, frontotemporal dementia, pseudodementia, alopecia, hair loss, wound healing, androgenetic alopecia (AGA), epilepsy, traumatic brain injury, hairy cell leukemia, non-small cell lung cancer, scleroderma, anterior eye disease, posterior eye disease, primary progressive multiple sclerosis, complex regional pain syndrome, viral infections (such as HIV infection), reflex sympathetic dystrophy, muscular dystrophy, causalgia, neuritis, neuroinflammatory disorders, bladder cancer, ureteral cancer, urethral cancer, umbilical cord Ductal cancer, basal cell carcinoma, bile duct cancer, colon cancer, endometrial cancer, esophageal cancer, Ewing's sarcoma, gastric cancer, glioma, hepatocellular carcinoma, Hodgkin's lymphoma, laryngeal cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, pancreatic cancer, rectal cancer, kidney cancer, squamous cell carcinoma, T-cell lymphoma, thyroid cancer, monocytic leukemia, pheochromocytoma, malignant peripheral nerve cell tumor, malignant peripheral nerve sheath tumor (MPNST), skin and plexiform neurofibromas, leiomyomatosis, fibroids, uterine fibroids, smooth muscle Sarcomas, papillary thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, follicular thyroid cancer, Schürthle cell adenocarcinoma, thyroid cancer, angiosarcoma, liposarcoma, ascites, malignant ascites, mesothelioma, salivary gland tumors, salivary gland mucoepidermoid carcinoma, salivary gland acinar cell carcinoma, gastrointestinal stromal tumors, tumors that cause fluid accumulation in potential spaces in the body, pleural effusions, other sarcomas; tumor angiogenesis and paracrine tumor growth; and tumors that aberrantly or otherwise express CSF1R or an activating mutation or translocation of any of the foregoing.
[0103] In another embodiment of the present invention, the CSF1R-mediated disease that can be treated by any of the crystalline forms of the compound of Formula I in the present invention is epilepsy.
[0104] In another embodiment of the present invention, the CSF1R-mediated disease treatable by any of the crystalline forms of the compound of Formula I of the present invention is traumatic brain injury.
[0105] In another embodiment of the present invention, CSF1R-mediated diseases that can be treated by any of the crystalline forms of the compound of Formula I of the present invention include tauopathies.
[0106] In another embodiment of the present invention, CSF1R-mediated diseases treatable by any of the crystalline forms of the compound of Formula I of the present invention include reducing viral reservoirs in a patient.
[0107] In another embodiment of the present invention, the CSF1R-mediated diseases that can be treated by any of the crystalline forms of the compound of Formula I of the present invention are anterior or posterior ocular diseases, including diseases of the cornea, conjunctiva, sclera, and lacrimal glands.
[0108] In another embodiment of the present invention, CSF1R-mediated diseases that can be treated by any of the crystalline forms of the compound of Formula I in the present invention include Erdheim Chester disease / Langerhans cell disease, hairy cell leukemia, and non-small cell lung cancer.
[0109] In another embodiment of the present invention, the disease that can be treated by any of the crystalline forms of the compound of formula I in the present invention is scleroderma; the formulation can be selected from topical formulations such as gels, creams or sprays.
[0110] In one embodiment of the present invention, the present disclosure provides a composition comprising a compound of the present disclosure and a pharmaceutically acceptable carrier or excipient, wherein the compound is selected from the group consisting of Formula I, Form A, Formula I, Form B, Formula I, Form C, Formula I, Form D, Formula I, Form E, and Formula I, Form F.
[0111] In another embodiment of the present invention, the capsules or tablets of the crystalline forms A, B, C, D, E and F of the compound of formula I of the present invention may be prepared by combining crystalline forms AF of the compound of formula I with a pharmaceutically acceptable carrier or excipient.
[0112] In another embodiment of the present invention, the composition comprises Form A of the compound of Formula I and Form B of the compound of Formula I. In another embodiment, the composition comprises Form A of the compound of Formula I and at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% w / w of Form B of the compound of Formula I. In yet another embodiment, the composition comprises Form A of the compound of Formula I and at least 50% w / w of Form B of the compound of Formula I.
[0113] Another embodiment of the present invention relates to preparing a capsule or tablet comprising the crystalline Form B of the compound of Formula I, comprising combining the crystalline Form B of the compound of Formula I with a pharmaceutically acceptable carrier or excipient.
[0114] Another embodiment of the present invention relates to preparing a tablet comprising the crystalline Form B of the compound of Formula I, comprising combining the crystalline Form B of the compound of Formula I with a pharmaceutically acceptable carrier or excipient.
[0115] In another embodiment of the present invention, the composition comprises Form B of the compound of Formula I. In another embodiment, the composition comprises at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% w / w Form B of the compound of Formula I.
[0116] In some embodiments of the present invention, the composition used in the method of the present invention will contain a pharmaceutically acceptable carrier or excipient, such as a filler, a binder, a disintegrant, a glidant, a lubricant, a solubilizer, and a surfactant, examples of which include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, different types of starch, cellulose derivatives, gelatin, or lipids, etc. Carriers also include physiologically compatible liquids as solvents or for suspensions, including, for example, sterile solutions of water for injection, physiological saline, dextrose solutions, vegetable oils, mineral oils, animal oils, polyethylene glycols, or liquid paraffin, etc. Excipients can also include, for example, colloidal silicon dioxide, silica gel, talc, magnesium silicate, calcium silicate, sodium aluminosilicate, microcrystalline cellulose, silicified microcrystalline cellulose, carboxymethyl cellulose, croscarmellose sodium, sodium benzoate, calcium carbonate, magnesium carbonate, stearic acid, aluminum stearate, calcium stearate, magnesium stearate, zinc stearate, magnesium oxide, starch, sodium starch glycolate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, hydrogenated vegetable oil, hydrogenated cottonseed oil, castor oil, mineral oil, polyethylene glycols (e.g., PEG-10), PEG-100, ... 4000-8000), poloxamer, povidone, crospovidone, alginic acid, docusate sodium, cyclodextrin, polysorbate (e.g., polysorbate 80), magnesium lauryl sulfate, sodium lauryl sulfate, mannitol, xylitol, sorbitol, maltose, lactose, sucrose, fructose, calcium phosphate, calcium hydrogen phosphate, calcium phosphate, calcium sulfate, polydextrose, dextrin, dextrose, cellulose acetate, maltodextrin, dimethicone, polydextrose, aminodextran, gelatin, HPMC (hydroxypropyl methylcellulose), HPC (hydroxypropyl cellulose) or hydroxyethyl cellulose, etc.
[0117] In some embodiments of the present invention, pharmaceutical preparations for oral use can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops. For example, tablets, coated tablets, hard capsules, soft capsules, solutions (e.g., aqueous solutions, alcoholic solutions, or oily solutions), etc. Suitable excipients are, in particular, fillers such as sugars (including lactose, glucose, sucrose), mannitol, or sorbitol; cellulose preparations, for example, microcrystalline cellulose, corn starch, wheat starch, rice starch, potato starch, methylcellulose, hydroxypropyl methylcellulose; gelatin, tragacanth gum, sodium carboxymethylcellulose (CMC), and / or polyvidone (PVP); oil-containing excipients, including vegetable oils and animal oils, such as sunflower oil, olive oil, or cod liver oil. Oral dosage form formulations may also contain disintegrants such as cross-linked polyvinylpyrrolidone, agar or alginic acid, or salts thereof such as sodium alginate; lubricants such as talc or magnesium stearate; plasticizers such as sorbitol; sweeteners such as sucrose, fructose, lactose or aspartame; natural or artificial flavorings such as mint, strawberry or cherry flavoring; or pigments or pigments that can be used to identify or characterize different dosage forms or combinations. Sugar-coated pill cores with suitable coatings are also provided. For this purpose, concentrated sugar solutions can be used, which may optionally contain, for example, gum arabic, talc, povidone, polyethylene glycol and / or titanium dioxide and a suitable organic solvent or solvent mixture.
[0118] Beneficial technical effects of the present invention: The preparation methods of the free PLX5622 solid forms of the present invention, i.e., the new crystal forms A, B, C, D, E, and F of the compound of formula I, have the advantages of simple operation, high yield, and are conducive to industrial production; the obtained crystal forms have stable quality, high purity, and good solubility. Therefore, the discovery of this crystal form is of great significance to the development of subsequent formulations and the development of pharmacy. Studies have shown that the prepared products, the new crystal forms A and B, have good particle size distribution, stable physical and chemical properties during long-term storage, and good pharmaceutical effects. The inventors have found that the pharmaceutical effects of crystal form B are better than those of crystal form A. Compared with crystal form A of the compound of formula I, crystal form B has an outstanding effect in clearing microglia, and the 7-day clearance rate or 14-day clearance rate of microglia is better than that of crystal form A.
[0119] Based on current research results, Form A has relatively stable physical and chemical properties, and its microglial elimination rate is pharmaceutically acceptable, but it is not as effective or as stable as Form B. Hydrate Form C and solvate Forms D, E, and F exhibit good solid-state crystallinity, fine particle size, and strong fluidity. The products are easily prepared. Form C, D, E, and F can be prepared into Form A or Form B after desolvation, providing a new method for preparing different target crystal forms. BRIEF DESCRIPTION OF THE DRAWINGS
[0120] FIG1 is an X-ray powder diffraction (XRPD) pattern of the free PLX5622 crystal form A of the present invention;
[0121] FIG2 is an X-ray powder diffraction (XRPD) pattern of the free PLX5622 crystal form B of the present invention;
[0122] FIG3 is a differential scanning calorimetry (DSC) spectrum of the free PLX5622 crystal form B of the present invention;
[0123] FIG4 is a polarizing microscope (PLM) photograph of the free PLX5622 crystal form B prepared by crystallization in Example 2.1 of the present invention;
[0124] FIG5 is a polarizing microscope (PLM) photograph of free PLX5622 Form B prepared by spray drying in Example 2.2 of the present invention;
[0125] FIG6 is an X-ray powder diffraction (XRPD) pattern of the free PLX5622 Form C of the present invention;
[0126] FIG7 is an X-ray powder diffraction (XRPD) pattern of the free PLX5622 crystal form D of the present invention;
[0127] FIG8 is a differential scanning calorimetry (DSC) spectrum of the free PLX5622 crystal form D of the present invention;
[0128] FIG9 is a thermogravimetric analysis (TGA) spectrum of the free PLX5622 crystal form D of the present invention;
[0129] FIG10 is an X-ray powder diffraction (XRPD) pattern of the free PLX5622 Form E of the present invention;
[0130] FIG11 is a differential scanning calorimetry (DSC) spectrum of the free PLX5622 crystal form E of the present invention;
[0131] FIG12 is a thermogravimetric analysis (TGA) spectrum of the free PLX5622 Form E of the present invention;
[0132] FIG13 is an X-ray powder diffraction (XRPD) pattern of the free PLX5622 Form F according to the present invention;
[0133] FIG14 is a differential scanning calorimetry (DSC) spectrum of the free PLX5622 Form F of the present invention;
[0134] FIG15 is a thermogravimetric analysis (TGA) spectrum of the free PLX5622 Form F of the present invention;
[0135] FIG16 is a diagram showing the effect of eliminating microglia after administration of free PLX5622 crystal form A and crystal form B of the present invention;
[0136] FIG17 is a DSC-TGA spectrum of the free PLX5622 crystal form B of the present invention;
[0137] Figure 18 is the XRPD pattern of the mixture of free PLX5622 Form A and Form B according to the present invention. DETAILED DESCRIPTION
[0138] The present invention will be further described below with reference to specific examples. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention.
[0139] The experimental methods in the following examples where specific conditions are not specified are generally carried out under conventional conditions or conditions recommended by the manufacturers.
[0140] Unless otherwise specified, the raw materials and reagents used in the examples are commercially available.
[0141] The room temperature in the examples refers to 20-35° C. Unless otherwise specified, the reagents were used directly without purification. All solvents were purchased from commercial suppliers, such as Aldrich, and used without treatment.
[0142] The XRPD spectra were collected on a DX-21700BH diffractometer. The X-ray powder diffraction method parameters are as follows:
[0143] X-ray reflection parameters: Cu, Kα
[0144] Tube voltage: 40 kilovolts (kV)
[0145] Tube current: 40 milliamperes (mA)
[0146] Slits: 2# scattering slit: 1°, 3# anti-scattering slit: 1°, 4# receiving slit: 0.3mm.
[0147] Scan mode: Step
[0148] Step angle: 0.02°, sampling time: 1s;
[0149] Scanning range: from 3.0 to 40.0 degrees
[0150] The DSC spectra were collected on a TA Instruments Discovery DSC 250 instrument. The differential scanning calorimetry analysis parameters were as follows:
[0151] Scan rate: 10°C / min
[0152] Protective gas: nitrogen
[0153] TGA spectra were collected on a TA Instruments Discovery TGA 55 instrument. The thermogravimetric analysis method parameters are as follows:
[0154] Scan rate: 10°C / min
[0155] Protective gas: nitrogen
[0156] The preparation of the compound PLX5622 of formula I was obtained by synthesis according to the route provided in Nature communications 2019; 10(1): 3758.
[0157] Example 1 Preparation of PLX5622 Form A
[0158] Example 1.1
[0159] 1g of the compound of Formula I was mixed with 50% of the excipient, hydropropyl methylcellulose acetate succinate (HPMCAS), and dissolved in 30mL of THF. The resulting solution was spray-dried at an inlet temperature of 80°C, and the mixture was shaken to obtain a spray solution. The resulting solution was sprayed on a BUCHI Mini Spray Dryer B-290 spray dryer with an inlet temperature of 95-100°C, an outlet temperature of 80°C, and a nitrogen flow rate of 450-605 L / hr. The resulting sample was vacuum-dried at 50±5°C for 40 hours to obtain an off-white solid. The X-ray powder diffraction pattern is shown in Figure 1.
[0160] Example 1.2
[0161] 10g of the compound of Formula I was mixed with 50% of the excipient, hydropropyl methylcellulose acetate succinate (HPMCAS), and dissolved in 300mL of THF. The resulting solution was spray-dried at an inlet temperature of 80°C, shaken, and mixed to obtain a spray solution. The resulting solution was sprayed on a BUCHI Mini Spray Dryer B-290 spray dryer with an inlet temperature of 95-100°C, an outlet temperature of 80°C, and a nitrogen flow rate of 450-605 L / hr. The resulting sample was vacuum-dried at 50±5°C for 40 hours to obtain an off-white solid. This off-white solid is the PLX5622 Form A described herein.
[0162] Example 1.3
[0163] 100g of the compound of Formula I was mixed with 50% of the excipient, hydroxypropyl methylcellulose acetate succinate (HPMCAS), and dissolved in 300mL of THF. The resulting solution was spray-dried at an inlet temperature of 80°C, shaken, and mixed to obtain a spray solution. The resulting solution was sprayed on a BUCHI Mini Spray Dryer B-290 spray dryer with an inlet temperature of 95-100°C, an outlet temperature of 80°C, and a nitrogen flow rate of 450-605 L / hr. The resulting sample was vacuum-dried at 50±5°C for 40 hours to obtain an off-white solid. This off-white solid is the PLX5622 Form A described herein. Form A has a melting point of 188-189°C.
[0164] Example 2: Preparation of PLX5622 Form B
[0165] Example 2.1 Preparation of Form B by Crystallization
[0166] At 5°C, 5g of the compound of Formula I was dissolved in 40ml (8v) N,N-dimethylacetamide (DMAC), stirred in 15ml (3v) of water, and allowed to crystallize for 1h. Then, 25ml (5v) of water was added, and the crystals were allowed to crystallize for 0.5h. The mixture was filtered and dried under vacuum at 60°C to obtain Form B. The XRPD pattern of Form B is shown in Figure 2; the differential scanning calorimetry (DSC) analysis is shown in Figure 3; and the polarizing microscope (PLM) photograph is shown in Figure 4. The XRPD pattern of Form B lacks characteristic peaks at 8.60° and 10.50°, which are characteristic diffraction peaks of Form A, indicating that Form B does not contain Form A.
[0167] Example 2.2: Preparation of Form B by Solvent Removal Method
[0168] Dissolve 100 g of the compound of Formula I in 3000 mL of THF, and shake the resulting solution until clear to obtain a spray solution. The resulting solution was sprayed on a BUCHI Mini Spray Dryer B-290 spray dryer with an inlet temperature of 50-100°C and a nitrogen flow rate of 450-615 L / hr. The resulting sample was vacuum dried at 25-60°C for 40 hours to obtain an off-white solid. This off-white solid is the PLX5622 Form B described herein. Polarizing microscopy (PLM) images are shown in Figure 5.
[0169] Example 3: Preparation of Form C
[0170] At 25°C, 5 g of the compound of formula I was dissolved in 60 ml (14 v) of N,N-dimethylacetamide (DMAC), stirred with 37.5 ml (7.5 v) of water, and allowed to crystallize for 1 h. The crystals were filtered and dried under vacuum at 60°C. The XRPD of the resulting crystal form C is shown in Figure 6.
[0171] Example 4: Preparation of Form D
[0172] Example 4.1
[0173] At 25°C, 30g of the compound of Formula I was dissolved in 210ml (7v) N,N-dimethylacetamide (DMAC). 75ml (2.5v) of water was added with stirring. The solution was incubated for 1 minute, then filtered. The resulting sample was an off-white solid. The XRPD pattern is shown in Figure 7, the differential scanning calorimetry (DSC) pattern is shown in Figure 8, and the thermogravimetric analysis (TGA) pattern is shown in Figure 9.
[0174] Example 4.2
[0175] At 5°C, 30 g of the compound of formula I was dissolved in 120 ml (4 v) of N,N-dimethylacetamide (DMAC), 30 ml (1 v) of water was added under stirring, and Form B seed crystals were added. The crystals were incubated for 3 hours and filtered to obtain an off-white solid. The off-white solid obtained is the PLX5622 Form D described herein.
[0176] Example 5: Preparation of Form E
[0177] At 25°C, 5g of the compound of Formula I was dissolved in 40ml (8v) of N,N-dimethylacetamide (DMAC). 5ml (1v) of water was added with stirring, then the temperature was lowered to 5°C and allowed to crystallize for 1-2 hours. 35ml (7v) of water was then added, and the crystallization was allowed to crystallize for 0.5 hours. The resulting sample was an off-white solid. The XRPD pattern is shown in Figure 10, the differential scanning calorimetry (DSC) pattern is shown in Figure 11, and the thermogravimetric analysis (TGA) pattern is shown in Figure 12.
[0178] Example 6: Preparation of Form F
[0179] At room temperature, 5 g of the compound of Formula I was dissolved in 35 ml (7 vol) of tetrahydrofuran. The mixture was then cooled to 5°C and allowed to crystallize for 1-2 hours before filtration. The resulting sample was an off-white solid. The XRPD pattern is shown in Figure 13 , the differential scanning calorimetry (DSC) pattern is shown in Figure 14 , and the thermogravimetric analysis (TGA) pattern is shown in Figure 15 .
[0180] Example 7: Drying conversion relationship and stability test of Form A, Form B, Form C, Form D, Form E and Form F
[0181] Crystal form A can remain stable when dried at high temperature;
[0182] Crystal form B can remain stable when dried at high temperature;
[0183] Form C is a hydrated form; this form can only be obtained in a mixed system with a high water content or a system containing only water. After high-temperature drying, the residual solvent and water can be removed from this form to convert it into Form A.
[0184] Form D is a single molecule of DMAC solvate, which, after drying and solvent removal, transforms into Form A;
[0185] Form E is a single molecule of DMAC solvate, which can be transformed into Forms A and B after drying to obtain mixed crystals;
[0186] Form F is a THF solvate molecule, which can be transformed into Form A or Form B after drying to obtain a mixed crystal.
[0187] Table 1 Summary of drying conditions for Form AF
[0188] Stability test of crystalline form A of compound PLX5622 of formula I
[0189] Table 2 Stability data of Form A
[0190] After sampling and analysis (XRPD) of the above samples during the processing, it was shown that the PLX5622 Form A described in the present invention did not undergo morphological changes under accelerated test conditions (40°C, 75% humidity) and low-temperature storage conditions (-20°C), and was able to maintain good physical and chemical stability.
[0191] Stability test of crystalline form B of compound PLX5622 of formula I
[0192] Table 3 Stability data of Form B
[0193] A comparison under the same conditions found that the stability of PLX5622 crystal form B did not change in morphology under accelerated test conditions (40°C, 75% humidity) and low-temperature storage conditions (-20°C), and it could also maintain good physical and chemical stability.
[0194] Example 8: Animal efficacy test
[0195] 1. Feeding: Mice should be fed for 3-6 days from the first day of arrival in the mouse room, using AIN-76A food.
[0196] Group A was administered with compound PLX5622 crystal form A, and group B was administered with compound PLX5622 crystal form B;
[0197] Formal administration: Administer the drug every other day, on days 1, 3, 5, 7, 9, 11, and 13. Weigh the drug each time and replace it with 4g of the drug per mouse (the mouse actually eats about 3g).
[0198] II. Collection: After anesthetizing the mouse, secure it with tape or a needle / pin. Use forceps to pull up the fur on the outside of the chest cavity and use scissors to cut the skin to expose the white xiphoid process. Carefully cut the diaphragm with fine scissors, taking care not to injure the heart above.
[0199] A small incision was made in the right atrium. The heart was secured with forceps. A needle was inserted into the left ventricle, close to the apex, at an angle roughly parallel to the midline of the heart. Deep red blood was observed to flow out. The first perfusion was with normal saline, followed by a second perfusion with 4% paraformaldehyde fixative.
[0200] 3. Sample Processing
[0201] Sucrose gradient dehydration: Obtained mouse brains were fixed overnight with 4% paraformaldehyde. The next day, dehydrated with 20% sucrose solution until the material sank to the bottom. The third dehydration was with 30% sucrose solution until the material sank to the bottom. Embedded sections: 25-40 μm sections were obtained to obtain the tissue to be stained.
[0202] 4. Dyeing
[0203] 1. After washing the sections, the primary antibody was blocked in 5% BSA in PBST for 2 hours.
[0204] 2. Primary antibody incubation: The primary antibody used was IBA1 (1:500) in 1% BSA in PBST at 4°C for at least 14 hours.
[0205] 3. Incubate with Alexa Fluor-conjugated secondary antibody at 1:500 in 1% BSA in PBST at room temperature for 2 hours.
[0206] 4. Wash with PBS 3-5 times, 10 minutes each time; after DAPI staining, add anti-quenching agent to block and dry overnight, then stain, photograph and analyze.
[0207] V. Statistics
[0208] Image J counting: All cells with complete microglial morphology need to be counted.
[0209] Table 4 PLX5622-Experimental results of different groups
[0210] All mice were 3-month-old male mice; clearance rates were the average clearance rates and the average number of microglial cells (whole-brain number).
[0211] The experimental results in Table 4 show that the feeding clearance rate of Group B is better, that is, the crystal form B has an outstanding effect in clearing microglia, and the 7-day clearance rate or 14-day clearance rate of microglia is better than that of crystal form A; the effect of eliminating microglia after administration of free PLX5622 crystal form A and crystal form B respectively is shown in Figure 16.
[0212] Example 9: DSC-TGA detection of Form B
[0213] The DSC-TGA spectra of Form B are shown in Figure 17. DSC analysis reveals that Form B exhibits an endothermic-exothermic effect at 181°C and an endothermic effect at 188°C. TGA analysis reveals that Form B exhibits almost no weight loss before 188°C. Combined with Figure 13, this indicates that Form B undergoes a polymorphic transformation upon heating at 181°C.
[0214] In addition, the XRPD spectrum of the mixture of Form A and Form B was tested using the aforementioned XRPD method. The results are shown in Figure 18. According to the XRPD spectra of Form A, Form B, and the mixture of Form A and Form B in Figure 18, it can be seen that the mixture of Form A and Form B has characteristic diffraction peaks unique to Form A at 8.60° and 10.50°, while the XRPD spectrum of Form B does not have these characteristic diffraction peaks, indicating that Form A is not present in Form B.
[0215] Therefore, the crystal form B prepared in this application is a pure crystal form.
[0216] Example 10: Pharmacokinetic determination in rats
[0217] Different crystalline forms of PLX5622 were uniformly mixed in AIN-76A standard feed at a dose of 1200 ppm. Groups of seven mice were divided into 7-day and 14-day groups. Plasma or brain samples were collected from both groups for pharmacokinetic (PK) analysis. For the 7-day group, plasma samples were drawn on days 1, 3, and 7; the mice were euthanized on day 7, and brain tissue samples were removed. For the 14-day group, plasma samples were drawn on days 10 and 14, and brain tissue samples were removed after euthanasia on day 14.
[0218] For plasma processing, animals were anesthetized on days 1, 3, 7, 10, and 14. Approximately 150 μL of blood was collected by cardiac puncture into anticoagulant tubes containing K2EDTA. Within 15 minutes of collection, plasma was obtained by centrifugation at 2000 g for 5 minutes at 4°C. Plasma samples were then stored at below -60°C until analysis. For brain tissue processing, mice were euthanized on days 7 and 14. Brain tissue was then dissected, washed with saline to remove residual blood, blotted dry with filter paper, weighed, and frozen on dry ice before being stored at below -60°C until analysis. Pharmacokinetic (PK) parameters, Cmax and AUC, were calculated using WinNonlin 8.2 software according to a non-compartmental model. Drug concentrations were measured in mouse plasma and brain tissue.
[0219] The experimental results showed that the crystal form B feed group exhibited better pharmacokinetic performance.
[0220] The above description is only a preferred specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto; any technician familiar with the technical field, within the technical scope disclosed by the present invention, who makes equivalent replacements or changes based on the technical solution and inventive concept of the present invention, should be covered by the scope of protection of the present invention.
Claims
1. A solid crystalline form of a compound of formula I having the following structural formula: The solid crystalline form of the compound of formula I includes Form A, Form B, Form C, Form D, Form E or Form F of the compound of formula I; The crystalline form A has characteristic absorption peaks at diffraction angles 2θ of 8.60±0.2°, 10.50±0.2°, and 13.80±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source; The crystalline form B has characteristic peaks at diffraction angles 2θ of 5.90±0.2°, 15.6±0.2°, and 17.2±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source; or has characteristic peaks at diffraction angles 2θ of 5.90±0.2°, 15.65±0.2°, and 17.20±0.2°; The crystalline form C has characteristic peaks at diffraction angles 2θ of 8.24±0.2°, 13.16±0.2°, and 16.40±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source; The crystalline form D has characteristic peaks at diffraction angles 2θ of 11.70±0.2°, 17.76±0.2°, and 15.92±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source; The crystalline form E has characteristic peaks at diffraction angles 2θ of 15.40±0.2°, 18.02±0.2°, and 19.68±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source; The crystal form F has characteristic peaks at diffraction angles 2θ of 8.98±0.2°, 9.82±0.2° and 17.08±0.2° in an X-ray powder diffraction pattern using a Cu-Kα radiation source.
2. The solid crystalline form according to claim 1, characterized in that: The crystalline form A of the compound of formula I comprises an X-ray powder diffraction pattern substantially as shown in FIG1 .
3. The solid crystalline form of the compound of formula I according to claim 1, characterized in that The solid crystalline form of the compound of formula I satisfies one or more of the following conditions: (1) The crystalline form A of the compound of formula I has an X-ray powder diffraction pattern with characteristic peaks at 2θ values of 8.60±0.2°, 13.80±0.2°, 18.38±0.2°, and 20.90±0.2°; preferably, the X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.60±0.2°, 10.50±0.2°, 13.80±0.2°, 14.66±0.2°, 17.18±0.2°, 18.38±0.2°, 20.90±0.2°, and 25.98±0.2°; more preferably, the X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.60±0.2°, 9.18±0.2°, 10.50±0.2°, 12.94±0.2°, 13. 80±0.2°, 14.66±0.2°, 16.67±0.2°, 17.18±0.2°, 17.70±0.2°, 18.38±0.2°, 18.90±0.2°, 19.46±0.2°, 20.08±0.2°, 20.90±0.2°, 22.02±0.2°, 23.86±0.2° , 24.74±0.2°, 25.62±0.2°, 25.98±0.2°, 26.70±0.2°, 27.40±0.2°, 27.70±0.2°, 28.48±0.2°, 29.44±0.2°, 29.76±0.2°, 30.86±0.2°, and 31.88±0.2° have characteristic peaks; (2) The crystalline form B of the compound of formula I has an X-ray powder diffraction pattern with characteristic peaks at 2θ values of 5.90±0.2°, 15.65±0.2°, 17.20±0.2° and 22.50±0.2°; preferably, the X-ray powder diffraction pattern has characteristic peaks at 2θ values of 5.90±0.2°, 9.18±0.2°, 15.65±0.2°, 17.20±0.2° and 22.50±0.2°. .84±0.2°, 21.64±0.2°, 22.50±0.2° and 27.64±0.2°; More preferably, its X-ray powder diffraction pattern has characteristic peaks at 2θ values of 5.90±0.2°, 9.18±0.2°, 11.70±0.2°, 14.16±0.2°, 15.65±0.2°, 17.20±0.2°, 17.84±0.2°, There are characteristic peaks at 19.86 ± 0.2°, 21.64 ± 0.2°, 21.99 ± 0.2°, 22.50 ± 0.2°, 23.88 ± 0.2°, 24.28 ± 0.2°, 24.52 ± 0.2°, 27.64 ± 0.2°, 28.10 ± 0.2°, and 28.40 ± 0.2°; (3) The crystalline form C of the compound of formula I has an X-ray powder diffraction pattern with characteristic peaks at 2θ values of 8.24±0.2°, 13.16±0.2°, 16.40±0.2°, 18.38±0.2° and 27.66±0.2°; preferably, the X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.24±0.2°, 13.16±0.2°, 13.74±0.2°, 16.40±0.2°, 17.72±0.2°, 18.38±0.2° , 20.42±0.2° and 27.66±0.2° have characteristic peaks; more preferably, its X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.24±0.2°, 9.26±0.2°, 13.16±0.2°, 13.74±0.2°, 16.40±0.2°, 17.72±0.2°, 18.38±0.2°, 20.42±0.2°, 24.72±0.2°, 27.24±0.2° and 27.66±0.2°; (4) The crystalline form D of the compound of formula I has an X-ray powder diffraction pattern with characteristic peaks at 2θ values of 11.70±0.2°, 17.76±0.2°, 15.92±0.2°, 20.46±0.2° and 29.08±0.2°; preferably, the X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.00±0.2°, 10.26±0.2°, 11.70±0.2°, 12.50±0.2°, 15.92±0.2°, 17.76±0.2°, 20.46 ± 0.2° and 29.08 ± 0.2°; more preferably, its X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.00 ± 0.2°, 10.26 ± 0.2°, 11.70 ± 0.2°, 12.50 ± 0.2°, 15.92 ± 0.2°, 17.76 ± 0.2°, 20.46 ± 0.2°, 26.88 ± 0.2°, 27.08 ± 0.2°, 27.34 ± 0.2°, 29.08 ± 0.2° and 29.36 ± 0.2°; (5) The crystalline form E of the compound of formula I has an X-ray powder diffraction pattern with characteristic peaks at 2θ values of 15.40±0.2°, 18.02±0.2°, 19.68±0.2°, 21.72±0.2° and 26.20±0.2°; preferably, the X-ray powder diffraction pattern has characteristic peaks at 2θ values of 10.24±0.2°, 13.44±0.2°, 15.40±0.2°, 17.16±0.2°, 18.02±0.2°, 19.68±0.2°, 20.82±0.2°, 21.72±0.2° and 26.20±0.2°; more preferably, the X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.98±0 .2°, 9.86±0.2°, 10.24±0.2°, 13.44±0.2°, 15.40±0.2°, 16.14±0.2°, 17.16±0.2°, 18.02±0.2°, 19.68±0.2°, 20.24±0.2°, 20.82±0.2°, 21.72±0.2°, 22.82±0.2°, 24.36±0.2°, 25.54±0.2°, 26.20±0.2°, 27.32±0.2°, 28.10±0.2°, 30.62±0.2°, 31.38±0.2°, 32.14±0.2° and 38.06±0.2°; (6) The crystalline form F of the compound of formula I has an X-ray powder diffraction pattern having characteristic peaks at 2θ values of 8.98±0.2°, 9.82±0.2°, 17.08±0.2° and 19.72±0.2°; preferably, the X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.98±0.2°, 9.82±0.2°, 17.08±0.2°, 18.00±0.2°, 19.72±0.2°, 20.96±0.2°, 22.14±0.2° and 25.00±0.2°; more preferably, Its X-ray powder diffraction pattern has characteristic peaks at 2θ values of 8.03±0.2°, 8.98±0.2°, 9.92±0.2°, 16.10±0.2°, 17.08±0.2°, 18.00±0.2°, 19.72±0.2°, 20.96±0.2°, 22.14±0.2°, 24.26±0.2°, 25.00±0.2°, 27.18±0.2°, 28.60±0.2°, 29.75±0.2°, 34.54±0.2° and 36.50±0.2°.
4. The solid crystalline form of the compound of formula I according to claim 1, characterized in that The solid crystalline form of the compound of formula I satisfies one or more of the following conditions: (1) The XRPD pattern of Form B of the compound of Formula I is consistent with Figure 2; (2) The XRPD pattern of Form C of the compound of Formula I is consistent with Figure 6; (3) The XRPD pattern of Form D of the compound of Formula I is consistent with Figure 7; (4) The XRPD pattern of Form E of the compound of Formula I is consistent with Figure 10; (5) The XRPD pattern of Form F of the compound of Formula I is consistent with that in FIG13 .
5. The solid crystalline form of the compound of formula I according to claim 1, characterized in that The solid crystalline form of the compound of formula I satisfies one or more of the following conditions: (1) The crystalline form A of the compound of formula I is an anhydrous crystalline form; (2) The crystalline form B of the compound of formula I is an anhydrous crystalline form; (3) The differential scanning calorimetry analysis spectrum of Form B of the compound of Formula I is shown in FIG3 , wherein Form B has endothermic peaks at 181°C±4°C and 188°C±4°C; (4) The differential scanning calorimetry analysis spectrum of Form D of the compound of Formula I is shown in FIG8 , wherein Form D has two relatively obvious sharp endothermic peaks in the range of 20°C-250°C, one of which is at 50°C-100°C and the other is at 189°C±3°C; (5) The differential scanning calorimetry analysis spectrum of the crystalline form D of the compound of formula I is shown in FIG9 , wherein the crystalline form D has an obvious weight loss at 50-100° C., and the weight loss mass percentage is 18%. The crystalline form D of the compound of formula I is a one-molecule N,N-dimethylacetamide DMAC solvent compound; (6) The differential scanning calorimetry analysis spectrum of the crystalline form E of the compound of formula I is shown in FIG11 , wherein the crystalline form E has multiple endothermic and exothermic peaks in the range of 20°C-250°C; one relatively obvious endothermic peak is near 90°C-120°C, and another is in the range of 150°C-200°C; (7) The differential scanning calorimetry analysis spectrum of the crystalline form E of the compound of formula I is shown in FIG12 , wherein, within the scanning temperature range of 20-300° C., the crystalline form E exhibits an obvious weight loss, with a weight loss mass percentage of 17%. The crystalline form E of the compound of formula I is a one-molecule N,N-dimethylacetamide (DMAC) solvent compound; (8) The differential scanning calorimetry analysis spectrum of Form F of the compound of Formula I is shown in FIG14 , wherein Form F has multiple endothermic and exothermic events in the range of 20°C-250°C; among them, there are three relatively obvious and sharp endothermic peaks, one at 78°C, one at 182±3°C, and another at 190°C±3°C; (9) The differential scanning calorimetry analysis spectrum of the crystalline form F of the compound of formula I is shown in FIG15 , wherein, within the scanning temperature range of 20-300° C., the crystalline form F has an obvious weight loss of 15%. The crystalline form F of the compound of formula I is a THF solvent compound.
6. The solid crystalline form of the compound of formula I according to claim 1, characterized in that The solid crystalline form of the compound of formula I satisfies one or more of the following conditions: (1) The crystalline form A of the compound of formula I is free of solvent, and the solvent comprises water; (2) The crystalline form B of the compound of formula I is free of solvent, and the solvent comprises water; (3) The crystalline form B of the compound of formula I further has an X-ray powder diffraction pattern having characteristic peaks at one or more of the following 2θ values: 9.18±0.2°, 17.84±0.2°, 21.64±0.2°, 22.50±0.2°, and 27.64±0.2°; more preferably, the X-ray powder diffraction pattern further has characteristic peaks at one or more of the following 2θ values: 11.70±0.2°, 14.16±0.2°, 19.86±0.2°, 21.99±0.2°, 23.88±0.2°, 24.28±0.2°, 24.52±0.2°, 28.10±0.2°, and 28.40±0.2°; (4) The differential scanning calorimetry spectrum of Form B of the compound of Formula I has two endothermic peaks at 181°C ± 4°C and 188°C ± 4°C; (5) The DSC spectrum of the crystalline form D of the compound of formula I has two absorption peaks at 50°C-100°C and 189°C±3°C; (6) The differential scanning calorimetry spectrum of Form D of the compound of Formula I shows a weight loss of 18% at 50-100°C; (7) The DSC spectrum of the crystalline form E of the compound of formula I has two absorption peaks at 107±3°C and 177±3°C, and an exothermic peak at 111±3°C; (8) The TGA spectrum of Form E of the compound of Formula I shows a weight loss of 16% at 50-110°C; (9) The DSC spectrum of Form F of the compound of Formula I has two absorption peaks at 79±3°C and 190±3°C, and an exothermic peak at 182±3°C; (10) The TGA spectrum of the crystalline form F of the compound of formula I shows a weight loss of 15% at 50-100°C.
7. The solid crystalline form of the compound of formula I according to claim 1, characterized in that The solid crystalline form of the compound of formula I satisfies one or more of the following conditions: (1) The DSC spectrum of Form B of the compound of Formula I is substantially as shown in FIG3 ; (2) The TGA spectrum of Form B of the compound of Formula I is substantially as shown in FIG17 ; (3) The DSC spectrum of Form D of the compound of Formula I is substantially as shown in FIG8 ; (4) The TGA spectrum of Form D of the compound of Formula I is substantially as shown in FIG9 ; (5) The DSC spectrum of Form E of the compound of Formula I is substantially as shown in FIG11 ; (6) The TGA spectrum of Form E of the compound of Formula I is substantially as shown in FIG12 ; (7) The DSC spectrum of Form F of the compound of Formula I is substantially as shown in FIG14 ; (8) The TGA spectrum of the crystalline form F of the compound of formula I is substantially as shown in FIG15 .
8. A method for preparing a solid crystalline form of a compound of formula I according to claim 1, characterized in that: The method for preparing the solid crystalline form of the compound of formula I is the method for preparing Form B of the compound of formula I, the method for preparing Form C of the compound of formula I, the method for preparing Form D of the compound of formula I, the method for preparing Form E of the compound of formula I, or the method for preparing Form F of the compound of formula I; The preparation method of the crystalline form B of the compound of formula I is a solvent removal method or a crystallization method; preferably, the solvent removal method comprises the following steps: dissolving the compound of formula I in a tetrahydrofuran solution; spray drying to remove the solvent; obtaining the crystalline form B of the compound of formula I; the crystalline form B of the compound of formula I can be further dried; preferably, the crystallization method comprises the following steps: dissolving the compound of formula I in an amide, alcohol, ester or any combination thereof solvent, and then adding an anti-solvent to crystallize the compound of formula I; preferably, the amide solvent is N,N-dimethylacetamide, and preferably, the anti-solvent is an alkane or water; The method for preparing the crystalline form C of the compound of formula I comprises the following steps: crystallizing the compound of formula I using a mixed solvent of N,N-dimethylacetamide (DMAC) and water to obtain the crystalline form C of the compound of formula I; preferably, using a mixed solvent of N,N-dimethylacetamide (DMAC) in an amount of 14 times the mass (g) of the compound of formula I in mL and water in an amount of 7.5 times the mass (mL) of the mixed solvent; The method for preparing the crystalline form D of the compound of formula I comprises the following steps: crystallizing the compound of formula I using a mixed solvent of N,N-dimethylacetamide (DMAC) and water to obtain the crystalline form D of the compound of formula I; preferably, using a mixed solvent of N,N-dimethylacetamide (DMAC) in a volume of 4 to 7 times (mL) based on the mass of the compound of formula I in grams and water in a volume of 1 to 2.5 times (mL) based on the mass of the compound of formula I in grams; The preparation method of the crystalline form E of the compound of formula I comprises the following steps: crystallizing the compound of formula I using a mixed solvent of N,N-dimethylacetamide (DMAC) and water to obtain the crystalline form E of the compound of formula I; preferably, using a mixed solvent of N,N-dimethylacetamide (DMAC) in an amount of 8 times the mass of the compound of formula I in mL and water in an amount of 5 times the mass of the compound of formula I in mL, cooling the mixture to 5° C., maintaining the temperature for 1-2 hours, adding water in an amount of 7 times the mass of the compound of formula I in mL, maintaining the temperature for 0.5 hours, and filtering to obtain; The preparation method of the crystalline form E of the compound of formula I comprises the following steps: the compound of formula I is crystallized in a tetrahydrofuran solution to obtain a crystalline form E of formula I compound crystal form F.
9. The method for preparing the solid crystalline form of the compound of formula I according to claim 8, characterized in that: The preparation method of the crystalline form B of the compound of formula I satisfies one or more of the following conditions: (1) In the solvent removal method, the volume mass ratio of the tetrahydrofuran to the compound of formula I can be 15-100 mL / g, for example, 30 mL / g; (2) The crystallization method further comprises the following steps: mixing water and mixture X to obtain a mixed solution A, and crystallizing; the mixture X is the compound of formula I and N,N-dimethylacetamide; the volume mass ratio of N,N-dimethylacetamide to the compound of formula I is 8 mL / g, and the volume mass ratio of water to the compound of formula I is 3 mL / g; the crystallization temperature may be -15-60°C, for example, 5°C; preferably, the crystallization method further comprises the following steps: mixing the mixed solution A with water, the volume mass ratio of water to the compound of formula I is 5 mL / g, and continuing crystallization; the crystallization temperature may be 0-25°C, for example, 5°C.
10. The solid crystalline form of the compound of formula I according to claim 1, characterized in that The solid crystalline form of the compound of formula I is any one of the following schemes: Scheme 1: The crystalline form B of the compound of formula I comprises: i) an X-ray powder diffraction pattern having characteristic peaks at 2θ values of 5.90±0.2°, 9.18±0.2°, 11.70±0.2°, 14.16±0.2°, 15.65±0.2°, 17.20±0.2°, 17.84±0.2°, 19.86±0.2°, 21.64±0.2°, 21.99±0.2°, 22.50±0.2°, 23.88±0.2°, 24.28±0.2°, 24.52±0.2°, 27.64±0.2°, 28.10±0.2°, and 28.40±0.2°; ii) an X-ray powder diffraction pattern substantially as shown in Figure 2; iii) a DSC differential scanning calorimetry thermogram comprising endothermic peaks near 181°C ± 4°C and 188°C ± 4°C; iv) a DSC thermogram substantially as shown in Figure 3; Scheme 2: The crystalline form B of the compound of formula I is prepared by the following method: Method 1: Solvent removal method: 1) dissolving the compound of formula I in an ether, alkane, alcohol, ester, water, or any combination thereof, and then removing the solvent to obtain the compound of formula I; wherein the solvent removal is selected from distillation or spray drying; 2) obtained by dissolving in an ether solvent and then spray drying; 3) dissolving the compound of Formula I in tetrahydrofuran solution; spray drying to remove the solvent; obtaining the crystalline form B of the compound of Formula I; optionally further drying the crystalline form B of Formula I; Method 2: Crystallization method: 1) Dissolving the compound of formula I in an amide, alcohol, ester, or any combination thereof, and then adding an anti-solvent to crystallize the compound of formula I; preferably, the amide is N,N-dimethylacetamide, and preferably, the anti-solvent is an alkane or water; Option 3 includes: i) an X-ray powder diffraction pattern having characteristic peaks at 2θ values of 8.24±0.2°, 9.26±0.2°, 13.16±0.2°, 13.74±0.2°, 16.40±0.2°, 17.72±0.2°, 18.38±0.2°, 20.42±0.2°, 24.72±0.2°, 27.24±0.2°, and 27.66±0.2°; ii) an X-ray powder diffraction pattern substantially as shown in Figure 6; iii) the crystalline form C of the compound of formula I, prepared by the following method: The compound of formula I is crystallized using a mixed solvent of N,N-dimethylacetamide (DMAC) and water to obtain Form C of the compound of formula I; preferably, a mixed solvent of 14 times the mass (g) of the compound of formula I in mL of N,N-dimethylacetamide (DMAC) and 7.5 times the mass (mL) of water is used; Scheme 4: The crystalline form D of the compound of formula I comprises: i) an X-ray powder diffraction pattern having characteristic peaks at 2θ values of 8.00±0.2°, 10.26±0.2°, 11.70±0.2°, 12.50±0.2°, 15.92±0.2°, 17.76±0.2°, 20.46±0.2°, 26.88±0.2°, 27.08±0.2°, 27.34±0.2°, 29.08±0.2°, and 29.36±0.2°; ii) an X-ray powder diffraction pattern substantially as shown in Figure 7; iii) a DSC differential scanning calorimetry thermogram comprising two relatively distinct and sharp endothermic peaks within the range of 20°C to 250°C, one of which is near 50°C to 100°C and the other of which is within the range of 189°C ± 3°C; iv) a DSC thermogram substantially as shown in Figure 8; v) comprising an obvious weight loss at 50-100° C., with the weight loss percentage being about 18%; the compound crystalline form D is a single molecule of N,N-dimethylacetamide (DMAC) solvent compound; vi) a TGA thermogravimetric analysis comprising a thermogram substantially as shown in FIG9 ; vii) Form D of the compound of formula I, prepared by a method comprising: The compound of formula I is crystallized using a mixed solvent of N,N-dimethylacetamide (DMAC) and water to obtain Form D of the compound of formula I; preferably, a mixed solvent of 4 to 7 times the mass of the compound of formula I (g) in volume mL of N,N-dimethylacetamide (DMAC) and 1 to 2.5 times the volume mL of water is used; Scheme 5: The crystalline form E of the compound of formula I comprises: i) X-ray powder diffraction patterns at 2θ values of 8.98±0.2°, 9.86±0.2°, 10.24±0.2°, 13.44±0.2°, 15.40±0.2°, 16.14±0.2°, 17.16±0.2°, 18.02±0.2°, 19.68±0.2°, 20.24±0.2°, 20.82±0 .2°, 21.72±0.2°, 22.82±0.2°, 24.36±0.2°, 25.54±0.2°, 26.20±0.2°, 27.32±0.2°, 28.10±0.2°, 30.62±0.2°, 31.38±0.2°, 32.14±0.2°, and 38.06±0.2°; ii) an X-ray powder diffraction pattern substantially as shown in Figure 10; iii) a DSC differential scanning calorimetry thermogram comprising two relatively distinct and sharp endothermic peaks in the range of 20°C to 250°C, one relatively distinct endothermic peak being near 90°C to 120°C, and the other being in the range of 150°C to 200°C; iv) a DSC thermogram substantially as shown in Figure 11; v) comprising an obvious weight loss at 50-100° C., with the weight loss percentage being about 17%; the compound crystalline form E is a single molecule of N,N-dimethylacetamide (DMAC) solvent compound; vi) a TGA thermogravimetric analysis comprising a thermogram substantially as shown in Figure 12; vii) the compound crystalline form E, prepared by the following method: The compound of formula I is crystallized using a mixed solvent of N,N-dimethylacetamide (DMAC) and water to obtain Form E of the compound of formula I; preferably, a mixed solvent of 8 times the volume of N,N-dimethylacetamide (DMAC) per g of the compound of formula I and 5 times the volume of water per mL is used, followed by cooling to 5° C., maintaining the temperature for 1-2 hours, then adding 7 times the volume of water per g of the compound of formula I, maintaining the temperature for 0.5 hours, and filtering to obtain; Scheme 6: The crystalline form F of the compound of formula I comprises: i) X-ray powder diffraction pattern at 2θ values of 8.03±0.2°, 8.98±0.2°, 9.92±0.2°, 16.10±0.2°, 17.08±0.2°, 18.00±0.2°, Characteristic peaks are found at 19.72 ± 0.2°, 20.96 ± 0.2°, 22.14 ± 0.2°, 24.26 ± 0.2°, 25.00 ± 0.2°, 27.18 ± 0.2°, 28.60 ± 0.2°, 29.75 ± 0.2°, 34.54 ± 0.2°, and 36.50 ± 0.2°; ii) an X-ray powder diffraction pattern substantially as shown in Figure 13; iii) a DSC differential scanning calorimetry thermogram comprising three relatively distinct and sharp endothermic peaks within the range of 20°C to 250°C, with one endothermic peak near 78°C, one within the range of 182±3°C, and another within the range of 190°C±3°C; iv) a DSC thermogram substantially as shown in Figure 14; v) comprising an obvious weight loss at 20-300° C., with the weight loss percentage being about 15%; wherein the crystalline form F of the compound of formula I is a THF solvent compound; vi) a TGA thermogravimetric analysis comprising a thermogram substantially as shown in Figure 15; vii) Form F of the compound of formula I, prepared by a method comprising: The compound of formula I is crystallized in tetrahydrofuran solution to obtain Form F of the compound of formula I.
11. Use of a solid crystalline form of Compound 1 according to any one of claims 1 to 7 and 10 in the preparation of a medicament for treating a subject having or at risk of developing neurofibromatosis or for treating a subject having or at risk of developing Alzheimer's disease or for restoring microglial function to improve rare and common neurodegenerative diseases.
Citation Information
Cited By
Pharmaceutical application of PLX5622
CN119837872A
